[1]宋成鑫,葛信国△,储 晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究*[J].陕西中医,2020,(11):1543-1547.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　SONG Chengxin,GE Xinguo,CHU Jing..Advanced gastric cancer treated by the method of nourishing Yin and invigorating spleen and dispersing toxin[J].,2020,(11):1543-1547.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
点击复制

养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年11期
页码:
1543-1547
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
Advanced gastric cancer treated by the method of nourishing Yin and invigorating spleen and dispersing toxin
作者:
宋成鑫; 葛信国△; 储 晶
江苏省常州市中医院肿瘤科(常州 213000)
Author(s):
SONG Chengxin; GE Xinguo; CHU Jing.
Department of Oncology,Changzhou Traditional Chinese Medicine Hospital in Jiangsu Province(Changzhou 213000)
关键词:
胃癌;  养阴健脾散毒法;  化疗;  免疫状态;  肿瘤标志物;  生活质量
Keywords:
Gastric cancer;  The method of nourishing yin and invigorating spleen and dispersing toxin;  Chemotherapy;  Immune status;  Tumor markers;  Quality of life
分类号:
R735.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.11.007
文献标志码:
A
摘要:
目的:观察养阴健脾散毒法辅助化疗干预晚期胃癌的效果,探讨其对患者免疫状态、血清肿瘤标记物、生活质量的影响。方法:选择80例晚期胃癌患者,按照随机数字表分为对照组和观察组,每组各40例。对照组患者单纯给予替吉奥/奥沙利铂(SOX)化疗,观察组患者给予养阴健脾散毒法辅助化疗干预,中药连续服用3个月,化疗进行3个周期。比较两组患者的中位无进展生存期、中医证候积分、T淋巴细胞亚群、血清肿瘤标志物、生活质量SF-36评分变化,观察用药过程中的不良反应。结果:观察组在晚期胃癌的治疗中存在更高生存优势(P<0.05); 治疗后与对照组相比,观察组患者中医证候积分显著降低(P<0.05); 观察组患者与机体免疫相关的CD3+、CD4+、CD4+/CD8+水平明显升高,CD8+水平则明显降低(P<0.05); 对照组患者治疗后与治疗前相比,CD3+、CD4+、CD4+/CD8+水平有所降低,但差异无统计学意义(P>0.05); 治疗后,观察组患者的血清肿瘤标志物CEA、CA19-9、CA125水平均显著低于对照组(P<0.05); 治疗后观察组患者的生活质量相关各评分与对照组相比显著升高(P<0.05); 观察组用药在减轻恶心呕吐、白细胞下降程度、改善贫血等方面效果明显优于对照组(P<0.05)。结论:养阴健脾散毒法辅助化疗干预晚期胃癌更利于提高患者的生存率,缓解临床症状,提高免疫功能,降低肿瘤标志物水平,显著改善患者的生活质量,且利于减轻化疗过程中的不良反应。
Abstract:
Objective:To observe the effect of the method of nourishing yin and invigorating spleen and dispersing toxin used to assist the chemotherapy in the treatment of advanced gastric cancer,and to explore its influence on patients' immune status,serum tumor markers and quality of life.Methods:Eighty patients with advanced gastric cancer were divided into control group and observation group,with 40 cases in each group.Patients in the control group were simply given tiggio/oxsliplatin(SOX)chemotherapy,while patients in the observation group were given the adjuvant chemotherapy intervention of nourishing Yin and invigorating spleen powder poisoning.The traditional Chinese medicine was taken for 3 months continuously,and the chemotherapy was carried out for 3 cycles.The median progression-free survival,TCM syndrome score,T lymphocyte subsets,serum tumor markers,and SF-36 score of quality of life were compared between the two groups,and the toxic and side effects of the drug were observed.Results:The observation group had a higher survival advantage in the treatment of advanced gastric cancer(P<0.05).The score of TCM syndrome in the observation group after treatment was significantly lower than that in the control group(P<0.05).The immune-related levels of CD3+,CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group,and the levels of CD8+ were significantly lower than those in the control group(P<0.05).After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the control group were lower than those before treatment,but the difference was not statistically significant(P>0.05).After treatment,the levels of serum tumor markers CEA,CA19-9 and CA125 in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the quality-of-life scores of the observation group were significantly higher than those of the control group(P<0.05).The observation group was significantly better than the control group in reducing nausea and vomiting,decreasing degree of white blood cells and improving anemia(P<0.05).Conclusion:The method of nourishing Yin,strengthening spleen and dispersing toxin to assist chemotherapy in the intervention of advanced gastric cancer is more conducive to improving the survival rate of patients,alleviating clinical symptoms,improving immune function,reducing the level of tumor markers,significantly improving the quality of life of patients,and reducing the toxic and side effects of chemotherapy,which has certain clinical promotion value.

参考文献/References:

[1] 庞芳宁,白 槟,杨 鹏,等.不同部位原发性胃癌临床病理特征对比研究[J].陕西医学杂志,2020,49(5):626-629.
[2] Ahadi A.Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression[J].IUBMB Life,2020,72(5):884-898.
[3] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[4] 张曼玲,时昭红,刘 云,等.胃癌前病变信号通路及相关中医药治疗的研究进展[J].天津中医药,2020,37(2):227-234.
[5] 国家卫生健康委员会.胃癌诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志,2019,5(1):55-82.
[6] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,1997:376-378.
[7] Ware JE,Sherbourne CD.The MOS 36-item short-form health survey(SF-36)[J].Medical Care,1992,30(6):473-483.
[8] 谢晶日,刘金狄,梁国英.益气养阴化瘀解毒方治疗胃癌前病变临床疗效观察[J].四川中医,2017,35(6):88-90.
[9] 卓少华,丘远聪,郑俊德,等.人参皂苷Rg5调控lncRNA-PCAT12抑制胃癌细胞生长实验研究[J].陕西中医,2020,41(4):437-439.
[10] 马艳春,冯天甜,韩宇博,等.藤梨根抗肿瘤作用机制及应用研究进展[J].中医药学报,2019,47(6):118-121.
[11] 王楠楠,黄飞华.红豆杉有效成分及其药理作用研究进展[J].浙江中医杂志,2018,53(8):621-623.
[12] 王单单,郭丽娜,裴 媛,等.基于网络药理学的半枝莲-白花蛇舌草药对作用机制分析[J].药物评价研究,2020,43(2):206-212.
[13] Zhao M,Liu Q,Liu WX,et al.MicroRNA140 suppresses Helicobacter pyloripositive gastric cancer growth by enhancing the antitumor immune response[J].Molecular Medicine Reports,2019,20(3):2484-2492.
[14] Zhou HB,Dong AL,Xia H,et al.Associations between CA199 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer[J].Oncology Letters,2018,16(1):1159.
[15] Pereira MA,Ramos MF,Dias AR,et al.Lymph node regression after neoadjuvant chemotherapy:A predictor of survival in gastric cancer [J].Journal of Surgical Oncology,2020,121(5):884-898.

相似文献/References:

[1]裴俊文,孙太振△,蒋立峰.基于对SGC7901细胞Survivin、Bcl2基因的调控 探讨益气化瘀散结方影响胃癌细胞增殖凋亡的作用机制*[J].陕西中医,2019,(4):411.
　PEI Junwen,SUN Taizhen,JIANG Lifeng..Study on the effect of Yiqi Huayu Sanjie decoction on the proliferation and apoptosis of gastric cancer cells based on the regulation of survivin and Bcl2 gene in SGC7901 cells[J].,2019,(11):411.
[2]高聪聪,范 筱,李 宁.益气健脾化积方对胃癌化疗疗效、患者安全性及预后影响的研究*[J].陕西中医,2019,(4):475.
[3]杨国强,闫强△.健脾解毒汤结合射频消融术治疗胃癌肝转移疗效研究[J].陕西中医,2019,(11):1510.
　YANG Guoqiang,YAN Qiang..Therapeutic effect of Jianpi Jiedu decoction combined with radiofrequency ablation on liver metastases from gastric cancer[J].,2019,(11):1510.
[4]马 婷,王品昊,朱 婕,等.行健汤联合穴位贴敷治疗进展期胃癌癌因性疲乏疗效及对患者免疫功能的影响*[J].陕西中医,2020,(10):1410.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.019]
[5]周 锐,马灏川,陈亚栋,等.针灸辅助治疗胃癌现状及展望[J].陕西中医,2021,(8):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
　ZHOU Rui,MA Haochuan,CHEN Yadong,et al.Review of acupuncture and moxibusition on gastric cancer[J].,2021,(11):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
[6]孟 肖,张新庆,李 璐,等.培元益气汤改善气阴两虚证胃癌相关癌性疲乏及对患者免疫功能的影响[J].陕西中医,2023,(2):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
　MENG Xiao,ZHANG Xinqing,LI Lu,et al.Peiyuan Yiqi decoction improves cancer-related fatigue of gastric cancer with deficiency of qi and yin and its effect on immune function[J].,2023,(11):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
[7]苏园园,刘宁宁,赖优莹,等.胃癌中医证型研究进展[J].陕西中医,2023,(2):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
　SU Yuanyuan,LIU Ningning,LAI Youying,et al.Progress in traditional Chinese medicine syndrome types research of gastric cancer[J].,2023,(11):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
[8]李琳婵,鱼麦侠,郝梅梅,等.调中化湿汤对胃癌小鼠炎症损伤干预机制[J].陕西中医,2023,(3):294.[doi:DOI:10.3969/j.issn.1000-7369.2023.03.005]
[9]熊 婷,薛川松,颜 晔.益气养血汤联合参芪扶正注射液治疗胃癌患者肿瘤相关性贫血疗效研究[J].陕西中医,2023,(8):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]
　XIONG Ting,XUE Chuansong,YAN Ye.Effect of Yiqi Yangxue decoction combined with Shenqi Fuzheng injection on cancer related anemia in patients with gastric cancer[J].,2023,(11):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]
[10]金 蕊,何卫才,郭甲民,等.培元化瘀解毒方联合新辅助化疗治疗胃癌临床观察[J].陕西中医,2023,(9):1227.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.016]
　JIN Rui,HE Weicai,GUO Jiamin,et al.Clinical observation on Peiyuan Huayu Jiedu formula combined with neoadjuvant chemotherapy in patients with gastric cancer[J].,2023,(11):1227.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.016]

备注/Memo

备注/Memo:
*江苏省中医药局科技项目(YB2017056)
更新日期/Last Update: 2020-11-09